Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel

Abstract

Summary Untargeted metabolomics is used to refine the development of biomarkers for the diagnosis of cardiovascular disease. Myocardial infarction (MI) has major individual and societal consequences for patients, who remain at high risk of secondary events, despite advances in pharmacological therapy. To monitor their differential response to treatment, we performed untargeted plasma metabolomics on 175 patients from the platelet inhibition and patient outcomes (PLATO) trial treated with ticagrelor and clopidogrel, two common P 2 Y 12 inhibitors. We identified a signature that discriminates patients, which involves polyunsaturated fatty acids (PUFAs) and particularly the omega-3 fatty acids docosahexaenoate and eicosapentaenoate. The known cardiovascular benefits of PUFAs could contribute to the efficacy of ticagrelor. Our work, beyond pointing out the high relevance of untargeted metabolomics in evaluating response to treatment, establishes PUFA metabolism as a pathway of clinical interest in the recovery path from MI.

METTL14-mediated N6-methyladenosine modification induces the ferroptosis of hypoxia/reoxygenation-induced cardiomyocytes

“…Ischemic heart disease represents a leading cause of medical burden worldwide [ 1 – 3 ]. Myocardial ischemia occurs when the coronary artery is obstructed with reduced blood supply to the dismal ischemic region causing heart dysfunction.…”

Simultaneous quantification of fatty acids in serum with dual derivatization by liquid chromatography‐tandem mass spectrometry

“…LCFAs are an important part of cell membranes and signaling molecules [11]. They also have anti‐inflammatory effects [12], and are related to obesity [13], stroke [14], cardiovascular [15], and cerebrovascular diseases [16]. Unsaturated LCFAs can be used as potential drugs for the treatment of obesity and cancer [17].…”